"Ethinyl Estradiol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.
| Descriptor ID |
D004997
|
| MeSH Number(s) |
D04.210.500.668.651.568.291 D06.472.334.851.437.968.500
|
| Concept/Terms |
Ethinyl Estradiol- Ethinyl Estradiol
- Estradiol, Ethinyl
- Ethinyloestradiol
- Ethynyl Estradiol
- Estradiol, Ethynyl
|
Below are MeSH descriptors whose meaning is more general than "Ethinyl Estradiol".
Below are MeSH descriptors whose meaning is more specific than "Ethinyl Estradiol".
This graph shows the total number of publications written about "Ethinyl Estradiol" by people in this website by year, and whether "Ethinyl Estradiol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ethinyl Estradiol" by people in Profiles.
-
Bansal R, Zoeller RT. CLARITY-BPA: Bisphenol A or Propylthiouracil on Thyroid Function and Effects in the Developing Male and Female Rat Brain. Endocrinology. 2019 08 01; 160(8):1771-1785.
-
Johnson-Agbakwu C, Brown L, Yuan J, Kissling R, Greenblatt DJ. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. Clin Ther. 2018 01; 40(1):64-73.
-
Jastrow A, Gordon DA, Auger KM, Punska EC, Arcaro KF, Keteles K, Winkelman D, Lattier D, Biales A, Lazorchak JM. Tools to minimize interlaboratory variability in vitellogenin gene expression monitoring programs. Environ Toxicol Chem. 2017 Nov; 36(11):3102-3107.
-
Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018 01; 218(1):68-74.
-
Carroll KJ, Esain V, Garnaas MK, Cortes M, Dovey MC, Nissim S, Frechette GM, Liu SY, Kwan W, Cutting CC, Harris JM, Gorelick DA, Halpern ME, Lawson ND, Goessling W, North TE. Estrogen defines the dorsal-ventral limit of VEGF regulation to specify the location of the hemogenic endothelial niche. Dev Cell. 2014 May 27; 29(4):437-53.
-
vom Saal FS, Akingbemi BT, Belcher SM, Crain DA, Crews D, Guidice LC, Hunt PA, Leranth C, Myers JP, Nadal A, Olea N, Padmanabhan V, Rosenfeld CS, Schneyer A, Schoenfelder G, Sonnenschein C, Soto AM, Stahlhut RW, Swan SH, Vandenberg LN, Wang HS, Watson CS, Welshons WV, Zoeller RT. Flawed experimental design reveals the need for guidelines requiring appropriate positive controls in endocrine disruption research. Toxicol Sci. 2010 06; 115(2):612-3.
-
Kaunitz AM, Burkman RT, Fisher AC, LaGuardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol. 2009 Dec; 114(6):1205-1212.
-
Burkman RT, Fisher AC, Wan GJ, Barnowski CE, LaGuardia KD. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception. 2009 Jun; 79(6):424-7.
-
Burkman RT, Fisher AC, LaGuardia KD. Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use. J Reprod Med. 2007 Nov; 52(11):1030-4.
-
Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol. 2007 Aug; 197(2):134.e1-6.